{"id":704123,"date":"2024-06-25T18:38:01","date_gmt":"2024-06-25T18:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=704123"},"modified":"2024-06-25T18:38:01","modified_gmt":"2024-06-25T18:38:01","slug":"microbiome-diagnostics-market-size-growth-opportunities-share-key-segments-regional-analysis-top-companies-and-forecast-to-2028","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/microbiome-diagnostics-market-size-growth-opportunities-share-key-segments-regional-analysis-top-companies-and-forecast-to-2028_704123.html","title":{"rendered":"Microbiome Diagnostics Market Size, Growth, Opportunities, Share, Key Segments, Regional Analysis, Top Companies and Forecast to 2028"},"content":{"rendered":"
\n
\"Microbiome<\/a><\/div>\n
\n
The Genetic Analysis (Norway) entered into an agreement with Eagle Biosciences Inc. (US) through its distributors with an undisclosed partner. A high-volume lab company providing laboratory diagnostics to clinics, public health departments and research universities in the US.<\/div>\n<\/div>\n<\/div>\n
The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.<\/div>\n

 Microbiome Diagnostics Market<\/a><\/strong> in terms of revenue was estimated to be worth $146 million in 2023 and is poised to reach $300 million by 2028, growing at a CAGR of 15.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The microbiome diagnostics market is driven by the growing demand of personalized medicine, the collaborative efforts between the microbiome industry and academia for microbiome research and increasing incidences of diseases in the microbiome-based diagnostics market. Growth in emerging countries and increased collaboration of industry players to work on new microbiome technology are anticipated to offer lucrative growth opportunities for the microbiome diagnostics market.<\/p>\n

Download an Illustrative overview: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=132581140<\/a><\/strong><\/p>\n

The kits & reagents accounted for the largest share of the microbiome diagnostics market, by product segment, in 2022.<\/strong><\/p>\n

The global microbiome diagnostics market is segmented into instruments and reagents & kits based on product. High consumption of consumables such as kits and reagents and their repeated purchases along with the increasing number of microbiome diagnostic tests performed across the globe, are the factors supporting the growth of the reagents & kits product segment.<\/p>\n

The hospitals segment accounted for the largest share of the microbiome diagnostics market, by end user, in 2022.<\/strong><\/p>\n

By end user, microbiome diagnostics market segmented into hospitals, research & academic institutes and, pharmaceutical & biotechnology companies. Hospitals are accounted for largest in the microbiome diagnostics market. The increasing prevalences of diseases such as gastrointestinal disorder, metabolic disorder etc. will boost the market growth.<\/p>\n

North America is the largest regional market for microbiome diagnostics market.<\/strong><\/p>\n

The global microbiome diagnostics market has been segmented into four major regions—North America, Europe, the Asia Pacific, and Rest of the World. In 2022, North America dominated the global microbiome diagnostics market in 2022. The large share of the North American market is primarily driven by the prevalence of chronic diseases, and the easy accessibility of technologically advanced instruments.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=132581140<\/a><\/strong><\/p>\n

Microbiome Diagnostics Market<\/strong> Dynamics:<\/strong><\/p>\n

Drivers:<\/strong><\/p>\n

    \n
  1. Growing prevalence of chronic diseases<\/li>\n
  2. Collaborative efforts between microbiome industry and academia for microbiome research<\/li>\n
  3. Growing demand for personalized medicine<\/li>\n
  4. Rising awareness about importance of human microbiomes<\/li>\n
  5. Rising funding and investments in microbiome research<\/li>\n<\/ol>\n

    Restraints:<\/strong><\/p>\n

      \n
    1. End-user budget constraints in developing countries<\/li>\n<\/ol>\n

      Opportunities:<\/strong><\/p>\n

        \n
      1. Increased collaboration between key players and small innovative companies to work on new microbiome technologies<\/li>\n<\/ol>\n

        Challenge:<\/strong><\/p>\n

          \n
        1. Adverse impact of complex regulatory policies on commercialization of microbiome<\/li>\n<\/ol>\n

          Key Market Players of <\/strong>Microbiome Diagnostics Industry<\/strong>:<\/strong><\/p>\n

          The major players operating in this market are DNA Genotek (Canada), Microba Life Sciences (US), and Genetic Analysis AS (Norway)<\/p>\n

          Get 10% Free Customization on this Report: https:\/\/www.marketsandmarkets.com\/requestCustomizationNew.asp?id=132581140<\/a><\/strong><\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           MarketsandMarkets\u2122 Research Private Ltd.<\/a>
          Contact Person:<\/strong> Mr. Aashish Mehra
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 18886006441
          Address:<\/strong>630 Dundee Road Suite 430
          City:<\/strong> Northbrook
          State:<\/strong> IL 60062
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.marketsandmarkets.com\/Market-Reports\/microbiome-diagnostics-market-132581140.html<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          The Genetic Analysis (Norway) entered into an agreement with Eagle Biosciences Inc. (US) through its distributors with an undisclosed partner. A high-volume lab company providing laboratory diagnostics to clinics, public health departments and research universities in the US. The report … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-704123","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/704123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=704123"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/704123\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=704123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=704123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=704123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}